Basic Information
Eisbach is a clinical-stage pioneer biotechnology company focused on precision oncology, aiming to disrupt tumor growth by targeting genetic vulnerabilities. The company develops allosteric drugs that selectively disrupt molecular mechanisms (also known as molecular machines) critical for tumor genomic reprogramming. Eisbach combines the identification of genetic vulnerabilities (synthetic lethality) present in tumors with its proprietary drug discovery platform ALLOS (targeting unique molecular vulnerabilities of its drug targets) to develop first-in-class therapies with fewer side effects. The company's pipeline includes several small-molecule candidates targeting chromatin remodeling, which enable effective combination therapies and inhibit resistance mechanisms in cancer treatment.